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Summary
Cytomegalovirus (CMV) infection has been implicated in accelerated T cell
ageing. End-stage renal disease (ESRD) patients have a severely immunologi-
cally aged T cell compartment but also a high prevalence of CMV infection.
We investigated whether CMV infection contributes to T cell ageing in ESRD
patients. We determined the thymic output by the T cell receptor excision
circle (TREC) content and percentage of CD31+ naïve T cells. The prolifera-
tive history of the T cell compartment by determination of the relative
telomere length (RTL) and the T cell differentiation status was determined
by immunophenotyping. It appeared that CMV infection did not affect
thymic output but reduced RTL of CD8+ T cells in ESRD patients. Moreover,
increased T cell differentiation was observed with higher percentages of
CD57+ and CD28null CD4+ and CD8+ memory T cells. These CD28null T
cells had significantly shorter telomeres compared to CD28+ T cells. There-
fore we concluded that CMV infection does not affect the decreased thymic
output but increases T cell differentiation as observed in ESRD-related pre-
mature T cell ageing.
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Introduction
Due to the progressive involution of thymic tissue, ageing of
the T cell compartment in healthy individuals is associated
with decreased numbers of circulating naive T cells. This
coincides with an increased differentiation status and pro-
liferative history of memory T cells. The process of immu-
nological T cell ageing is related to an age-related decline in
cellular immunity, resulting in reduced vaccination efficacy,
enhanced susceptibility for infectious diseases and a higher
risk for the development of tumours [1–5]. Higher
numbers of differentiated CD4+ T cells have also been asso-
ciated with a higher prevalence and severity of atheroscle-
rotic disease [6–9]. We recently documented that patients
with end-stage renal disease (ESRD) have a profound pre-
maturely aged T cell system which is believed to be caused
by the uraemia-induced proinflammatory conditions
[10,11]. The immunological age was determined using three
parameters: thymic output of newly formed T cells, the dif-
ferentiation profile of T cells and their relative telomere
length. The thymic function can be measured by T cell
receptor excision circles (TREC), which are small circular
DNA episomes created in T cell precursors that are formed
in the thymus during rearrangement of T cell receptor
(TCR) genes [12] and the expression of CD31 on naive T
cells [10]. Based on these parameters, the average immuno-
logical age of T cells in ESRD patients is 20–30 years higher
than that of healthy individuals [10].
Because infection with cytomegalovirus (CMV) has a
profound effect on the circulating T cell compartment in
healthy individuals, CMV has been implicated in immuno-
logical ageing. For instance, CMV-infected individuals
(CMV-seropositive) have a more differentiated memory T
cell compartment, a decreased CD4/CD8 ratio, an expan-
sion of CD4+ and CD8+ T cells lacking CD28 but expressing
CD57 [7,13–15] and a reduction in their T cell telomere
length, indicating an increased proliferative history of the T
cells [16]. These effects of CMV on the T cell compartment
are relevant, as a large population of healthy individuals is
infected with CMV [17]. The prevalence ranges between 30
and 100%, increases with age and is dependent upon an
individual’s socio-economic and ethnic background [8].
More than 70% of ESRD patients are CMV-seropositive,
and we have shown previously that a seropositive CMV
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status is associated with an increased differentiation status
of the T cells as determined by phenotyping of the T cell
compartment [7,14]. However, no information is available
on other parameters of immunological ageing, such as
TREC content, recent thymic emigrants and telomere
length, in relation to CMV serostatus in ESRD patients.
In this study we tested the hypothesis that CMV infection
in ESRD patients may play an important role in all
aspects of premature immunological ageing of the T cell
compartment.
Materials and methods
Study population
ESRD patients, defined by an estimated glomerular filtra-
tion rate of ≤15 ml/min/m2 by the Modification of Diet in
Renal Disease (MDRD) formula, and with or without dialy-
ses, were included. Patients were excluded if they had an
infection, malignancy, autoimmune disease or a history of
immunosuppressive drugs (including previous kidney
transplantations). CMV-seronegative and -seropositive
ESRD patients were age- and sex-matched as well as
matched for all or not receiving renal replacement therapy
(haemodialysis or peritoneal dialysis). Patients receiving
anti-viral therapy (i.e. valganciclovir) were excluded from
the study. Their clinical characteristics are shown in Table 1.
All individuals included gave informed consent and the
study was approved by the local medical ethical committee
(METC number: 2012-022). It was conducted according to
the principles of the Declaration of Helsinki and in compli-
ance with the regulations of International Conference on
Harmonization/Good Clinical Practice.
CMV serology
At the diagnostic department of Virology (Erasmus Medical
Center, Rotterdam, the Netherlands), serum immunoglobu-
lin (Ig)G antibodies to CMV were measured with an
enzyme immunoassay (Biomerieux, Vidas, Lyon, France)
and expressed as arbitrary units/ml (AU/ml). In line with
the manufacturer’s guidelines, an outcome of 6 AU/ml was
considered positive with respect to the presence of CMV-
specific IgG antibodies. In addition, the absence of serum
antibodies IgM to CMV as well as a negative polymerase
chain reaction (PCR) for CMV (no detectable level of viral
DNA), both determined at the diagnostic department of
Virology, served only to include CMV-seropositive patients
with a latent CMV infection.
PBMCs isolation
Peripheral blood mononuclear cells (PBMCs) were isolated
from blood samples drawn from clinically stable ESRD
patients on the day of visiting the out-patient clinic [10].
Two million PBMCs were snap-frozen for the TREC assay;
the remaining cells were frozen in liquid nitrogen with a
minimum amount of 10 × 106 cells per vial for further
experiments.
DNA isolation and TREC assay
TREC content was assessed using snap-frozen PBMCs.
Briefly, DNA was isolated according to the manufacturer’s
instructions (Qiagen Isolation kit; Qiagen, Venlo, the Neth-
erlands). Subsequently, TREC content was determined
using quantitative PCR. A combination of two primers and
a hydrolysis probe specific for the so-called δREC(TCRD)-
ψJα(TCRA) TREC (sjTREC) was employed. TaqMan quan-
titative PCR was performed on 50 ng DNA in a 25-μl
reaction mixture containing 700 nmol/l of each primer,
5′-TCGTGAGAACGGTGAATGAAG-3′ and 5′-CCATGCTG
ACACCTCTGGTT-3′, 150 nmol/l of hydrolysis probe 5′-
(FAM) CACGGTGATGCATAGGCACCTGC-3′ (TAMRA),
and 12·5 μl ×2 TaqMan Universal PCR Master Mix (Applied
Table 1. Study population characteristics
CMV-seronegative ESRD patients CMV-seropositive ESRD patients
Young Old Young Old
Number of individuals 38 38 42 41
Age (years) 33·7 ± 9·4† 61·3 ± 7·7† 36·9 ± 7·8† 64·6 ± 8·4†
Male 69·4% 78·2% 54·7% 61·6%
CMV titre (AU/ml) – – 70·9 ± 5·04† 75·8 ± 2·92†
Underlying kidney disease
Hypertensive nephropathy 6 (15·8%) 9 (23·7%) 10 (23·8%) 14 (34·1%)
Primary glomerulopathy 9 (23·7%) 9 (23·7%) 10 (23·8%) 5 (12·2%)
Diabetic nephropathy 0 (0%) 3 (7·9%) 1 (2·4%) 3 (7·3%)
Polycystic kidney disease 0 (0%) 2 (5·3%) 2 (4·8%) 2 (4·9%)
Reflux nephropathy 8 (21·1%) 2 (5·3%) 4 (9·5%) 3 (7·3%)
Other 8 (21·1%) 7 (18·4%) 9 (21·4%) 6 (14·6%)
Unknown 7 (18·4%) 6 (15·8%) 6 (14·3%) 8 (19·5%)
†Data are given in means with standard deviation. CMV: cytomegalovirus; ESRD: end-stage renal disease.
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Biosystems, Nieuwerkerk a/d IJssel, the Netherlands).
Quantification of the DNA amount in each sample was
performed using a quantitative PCR of the single-copy
albumin gene. All reactions were performed in duplicate,
unless a threshold cycle (Ct) difference between replicates of
>1·5 necessitated repeating the PCR experiment. ΔCt was
calculated by using the formula: Ct value TREC PCR − Ct
value albumin PCR [10,12].
Telomere length assay
Flow fluorescence in-situ hybridization was performed to
determine the telomere length of CD4+ and CD8+ T cells.
The isolated PBMCs were stained with either CD4-biotin
(Beckman-Coulter, BV, Woerden, the Netherlands) or CD8-
biotin (Biolegend, Europe BV, Uithoorn, the Netherlands)
followed by staining with streptavidin-cyanin 5 (Cy5)
(Biolegend). The PBMCs were fixed and permeabilized
(Invitrogen Life Technologies, Bleiswijk, the Netherlands)
and then, using the telomere PNA-kit/fluorescein
isothiocyanate (FITC) (Zebra Bioscience BV, Enschede, the
Netherlands), we determined the relative telomere length.
The subcell-line 1301 of CCRF-CEM, which is known to
have long telomeres, was used to calculate the relative
telomere length (RTL) of the CD4+ and CD8+ T cells using
the following formula [18]:
RTL
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In addition, PBMCs of five elderly CMV-seropositive ESRD
patients were sorted into a purified CD28+ or CD28null CD4+
or CD8+ T cell fraction to examine whether or not the
relative telomere length differed in these sorted T cell
fractions. For this purpose, PBMCs (20 × 106) were stained
with AmCyan-labelled anti-CD3 (BD Biosciences,
Erembodegem, Belgium), Pacific Blue-labelled anti-CD4
(BD Biosciences), allophycocyanin (APC)-labelled anti-
CD8 (BD Biosciences), phycoerythrin (PE)-labelled anti-
CD28 (BD Biosciences) and with 7-aminoactinomycin D
(7AAD) (BD Biosciences). Sorting was performed on a
FACSAria II SORP (BD Biosciences). All fractions had a
purity of more than 95%.
Telomerase activity assay
The activity of the telomerase enzyme was measured in five
CMV-seropositive and five age-matched CMV-seronegative
ESRD patients using the TRAPeze® XL telomerase detection
kit (Millipore, Temecula, CA, USA), according to the manu-
facturer’s instructions. Briefly, PBMCs (20 × 106) were
sorted into purified and viable CD4+ and CD8+ T cell frac-
tions (according to the sort protocol described briefly under
Telomere length assay).
The sorted T cell fractions (all with a purity of more than
95%) were stimulated with anti-CD3/CD28 beads (25 μl/
1 ml; Invitrogen Life Technologies) for 3 days at 37°C. Next,
cells were resuspended in CHAPS lysis buffer (provided in
the kit) and cell extractions were made (10–750 μg). Protein
levels were determined by using the Bio-Rad protein assay
(Bio-Rad, München, Germany).
This assay is based on the capacity of a test sample to
amplify a telomere template. The activity is expressed in
total product-generated (TPG) units, which is calculated
using the TSR8 standard curve (provided in the kit).
Differentiation status of T cells
A whole blood staining was performed to determine the T
cell differentiation status [10,11,14]. Briefly, whole blood
was stained with AmCyan-labelled anti-CD3 (BD
Biosciences) in combination with Pacific Blue-labelled anti-
CD4 (BD Biosciences) and APC-Cy70-labelled anti-CD8
(BD Biosciences). The T cells are defined as CD4+ or CD8+
and defined further into four different subsets based on the
expression of CCR7 and CD45RO. In Supporting informa-
tion Fig. S1, a typical example of the gating strategy is
depicted. Naive T cells are defined as CCR7+ and CD45RO–,
central memory (CM) cells as CCR7+ and CD45RO+, effec-
tor memory (EM) cells such as CCR7– and CD45RO+ and
EMRA cells such as CCR7− and CD45RO−. Expression was
determined by staining with FITC-labelled anti-CCR7
(R&D Systems, Uithoorn, the Netherlands) and APC-
labelled anti-CD45RO (BD Biosciences). T cell differentia-
tion is associated with loss of CD28 expression on the cell
surface. The ratio CD28+/CD28− (or CD28null) T cells within
the T cell subsets were determined by staining with
peridinin chlorophyll-Cy5·5 (PerCP-Cy5·5)-labelled anti-
CD28 (BD Biosciences) and the ratio CD57−/CD57+ was
determined by staining with APC-labelled anti-CD57
(Biolegend). To determine the thymic output of naive T
cells, the percentage of CD31+ naive T cells was determined
by staining with PE-labelled anti-CD31 (Biolegend)
[10,11,14].
Ki-67 staining of T cells
To quantify the percentage of dividing cells, we stained the
cells intracellularly with FITC-labelled anti-Ki-67 after fixa-
tion and permeabilization (IntraSure Kit; BD Biosciences).
Ki-67 is a nuclear antigen which is expressed selectively in
cells that are in the G-M stage of cell division. The fre-
quency of Ki-67+ cells was determined in the total CD4+ and
CD8+ T cell population.
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Statistical analyses
Differences between CMV-seropositive and CMV-
seronegative young (age < 50 years) and elderly (age ≥ 50
years) ESRD patients were analysed using the Mann–
Whitney U-test. For TREC content and RTL, a linear regres-
sion model was used. In addition, Spearman’s rho
correlation coefficients (Rs) were calculated to determine
the strength of the association between TREC content or
RTL with age for CMV-seropositive and CMV-seronegative
ESRD patients. A paired t-test was performed to calculate
significant differences in RTL between CD28+ T cells and
CD28null T cells. All statistical tests were performed two-
sided, while a P-value of <0·05 was considered significant.
Results
CMV infection does not influence thymic output of
naive T cells
Both CMV-seropositive and -seronegative ESRD patients
showed a decrease (reflected by an increase ΔCt) in TREC
content with increasing age (Fig. 1). The loss of TREC
content was similar in both patient groups; comparison of
the two lines showed that there were no significant differ-
ences in thymic output of naive T cells. (Fig. 1a). In accord-
ance with this finding, no significant differences in
percentages of CD31+ naive T cells (recent thymic emi-
grants) were detected between the CMV-seropositive and
-seronegative patients for the CD4+ (Fig. 1b) and CD8+ T
cell compartments (Fig. 1c).
In addition, no significant differences were observed
when considering absolute numbers [cells/μl, mean ±
standard error of the mean (s.e.m.)] of CD31 expressing
naive T-CD4+ (young: CMV-seropositive: 151·9 ± 24·42
versus CMV-seronegative: 173·6 ± 27·04 and old: CMV-
seropositive: 121·4 ± 14·32 versus CMV seronegative:
137·2 ± 13·38) and CD8+ (young: CMV-seropositive:
127·6 ± 15·36 versus CMV-seronegative: 101·6 ± 15·62 and
old: CMV-seropositive: 55·21 ± 5·11 versus CMV seronega-
tive: 78·8 ± 7·74) T cells.
CMV infection contributes to telomere attrition of
CD8+ but not CD4+ T cells, but does not affect the
activity of the telomerase enzyme
With increasing age, the RTL of CD4+ (Fig. 2a) and CD8+
(Fig. 2b) T cells declines in both CMV-seropositive and
-seronegative ESRD patients. CMV did not contribute sig-
nificantly to telomere attrition within CD4+ T cells (P = 0·2,
Fig. 2a), but the RTL of the CD8+ T cells was significantly
lower in patients with a latent CMV infection (P = 0·04)
(Fig. 2b).
Using linear regression analysis for chronological age and
the RTL of the CD8+ T cells, we were able to estimate the
effect of CMV infection on the immunological age of an
ESRD patient. For example, the average RTL of a CMV-
infected ESRD patient with a chronological age of 40 years
was similar to the average RTL of a 60-year-old CMV-
seronegative patient.
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Fig. 1. Quantification of T cell receptor excision circle (TREC)
content by real-time quantitative polymerase chain reaction (qPCR)
and CD31 expression by naive T cells to measure thymic output. The
thymic output was measured by two parameters. First, the TREC
content was determined (a). The threshold cycle (Ct) is the number of
amplification cycles needed to detect the TRECs and is a relative
measure, related inversely with the concentration of TRECs. Control
for DNA input was conducted by performing a qPCR for albumin and
the difference between the Ct for TRECs and the Ct for albumin was
calculated. The x-axis represents the age and on the y-axis the ΔCt
value is depicted. The ΔCt values of cytomegalovirus
(CMV)-seropositive end-stage renal disease (ESRD) patients (closed
symbols) are represented by the closed line; that of CMV-seronegative
ESRD patients (open symbols) by the dashed line. Next the patients
were separated based on their age (young: <50 years and old: ≥50
years) and the percentage of CD31+ naive CD4+ (b) as well as CD8+
(c) T cells were determined as a marker for thymic output. Statistical
differences between groups are shown, i.e. one symbol: P < 0·05; two
symbols: P < 0·01; three symbols: P < 0·001) and medians are shown.
Individual data-points are shown for CMV-seropositive patients
(closed symbols) and CMV-seronegative patients (open symbols).
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Upon dissection of CMV-seropositive as well as CMV-
seronegative ESRD patients into a younger (<50 years) and
an older (≥50 years) population, no differences were
observed in RTL for the CD4+ T cells between CMV-
seropositive and -seronegative age-matched groups
(Fig. 2c). Younger CMV-seropositive ESRD patients had sig-
nificantly (P < 0·05) shorter telomeres within their CD8+ T
cell compartment (mean RTL ± s.e.m.; 11·19 ± 0·83%)
when compared to CMV-seronegative age-matched coun-
terparts (13·28 ± 0·75%).
Next, we examined if CMV seropositivity is associated
with activity of the telomerase enzyme in the CD4+ and
CD8+ T cell compartment. Telomerase activity (expressed in
TPG units) was similar between CMV-seronegative and
CMV-seropositive patients for the CD4+ T cells (mean
TPG ± s.e.m.; CMV-seronegative: 0·54 ± 0·004 versus CMV-
seropositive: 0·55 ± 0·006) and CD8+ T cells (CMV-
seronegative: 0·55 ± 0·002 versus CMV-seropositive: 0·55 ±
0·002).
CMV-related changes in differentiation status of T cells
and relation to RTL
The significantly lower CD4+ naive/memory ratio (P < 0·05)
indicated a shift towards the memory phenotype within the
CD4+ T cell compartment of CMV-seropositive patients
(Fig. 3a). Dissection of the memory CD4+ T cells into CM
and EM did not show significant CMV-associated differ-
ences (data not shown). Next, we determined the differen-
tiation status by examining the loss in CD28 expression and
increase in CD57 expression. CMV-infected ESRD patients
had, on average, a significantly lower CD28+/CD28−
(P < 0·01) (Fig. 3b) and CD57−/CD57+ ratio (Fig. 3c) within
their CD4+ T cell compartment [P < 0·01 (young) and
P < 0·001 (elderly), respectively], indicative of CMV-
induced increased differentiation of CD4+ T cells. Moreover,
we determined the percentages of highly differentiated (i.e.
having a senescent phenotype) CD28null CD57+ T cells
within the CD4+ T cell compartment for CMV-seropositive
and age-matched CMV-seronegative ESRD patient popula-
tions. CMV-seropositive ESRD patients had significantly
higher percentages of these cells in their circulation than
age-matched CMV-seronegative ESRD patients (mean ±
s.e.m.; young CMV seropositive: 9·90% ± 3·48 versus young
CMV seronegative: 0·42% ± 0·23, P < 0·01 and old CMV
seropositive: 26·62% ± 4·27 versus old CMV seronegative:
5·78% ± 3·52, P < 0·001).
We also compared the RTL of sorted CD4+CD28null to
that of CD4+CD28+ (purity > 95%) T cells and found that
the CD4+CD28null T cells had significantly shorter telomeres
(P < 0·01) compared to the CD4+CD28+ T cells (Fig. 3d).
CMV affected the CD8+ T cell compartment more pro-
foundly than the CD4+ T cell compartment. CMV-
seropositive ESRD patients had a significantly (P < 0·05)
lower CD8 naive/memory ratio (Fig. 4a), due to a higher
number of memory CD8+ T cells consisting of a large popu-
lation of terminally differentiated CD8+ EMRA T cells
(absolute numbers: CMV-seronegative: 0·03 × 106, CMV-
seropositive: 0·12 × 106, P < 0·05). This was reflected by the
significantly lower CD28+/CD28− (Fig. 4b) (P < 0·001) and
CD57−/CD57+ ratio (Fig. 4c) [P < 0·01 (young) and P <
0·001 (elderly), respectively]. Similarly, as observed for
the CD4+ T cell compartment, a significantly higher pro-
portion of CD8+ T cells had a senescent phenotype in
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Fig. 2. Relative telomere length (RTL) of
circulating CD4+ and CD8+ T cells. The RTL
was determined for CD4+ (a) and CD8+ (b) T
cells of cytomegalovirus (CMV)-seropositive
(closed symbols, closed line) and
CMV-seronegative (open symbols, dashed line)
end-stage renal disease (ESRD) patients. Next,
patients were separated based on their age in a
young (age < 50 years) and an old (age ≥ 50
years) group and the RTL of CD4+ (c) and
CD8+ T cells (d) are shown for each group.
Significant differences between groups are
shown (one symbol: P < 0·05; two symbols:
P < 0·01; three symbols: P < 0·001). Individual
data-points with medians are depicted.
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CMV-seropositive ESRD patients when compared to their
age-matched CMV-seronegative counterparts (young
CMV-seropositive: 50·56% ± 3·77 versus young CMV-
seronegative: 15·56% ± 4·99, P < 0·01 and old CMV-
seropositive: 47·15% ± 4·09 versus old CMV-seronegative:
27·94% ± 5·16, P < 0·05).
Also, for the CD8+ T cells we determined the RTL
in CD28null and CD28+ T cell-sorted populations. The
CD8+CD28null T cells had significantly shorter (P < 0·01)
telomeres than the CD8+CD28+ T cells (Fig. 4d).
In an attempt to explain the additional telomere attrition
induced by CMV, we determined whether CMV infection
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Fig. 3. CD4+ T cell phenotype and
differentiation status and the correlation with
the relative telomere length (RTL). The ratio
CD4+ naive/memory T cells were determined
for cytomegalovirus (CMV)-seronegative and
CMV-seropositive end-stage renal disease
(ESRD) patients (a). Moreover, the ratio
CD4+CD28+/CD28− (b) and CD57−/CD57+ (c)
were calculated to determine the differentiation
status of the CD4+ T cell compartment. ESRD
patients were dissected into a young (age < 50
years) and an old (age ≥ 50 years) group.
Individual dots are shown with the median for
the CMV-seronegative patient population (open
symbols) and the CMV-seropositive patients
(closed symbols). Significant differences
between groups are shown (one symbol:
P < 0·05; two symbols: P < 0·01; three symbols:
P < 0·001). Next, the RTL was determined
within a sorted CD28+ and CD28null CD4+ T cell
population of 5 CMV-seropositive ESRD
patients (d). Individual data points are shown
and significant differences between the two T
cell fractions are shown (two symbols:
P < 0·01).
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Fig. 4. CD8+ T cell phenotype and
differentiation status and the correlation with
the relative telomere length (RTL). The ratio
CD8+ naive/memory T cells were determined in
cytomegalovirus (CMV)-seronegative and
CMV-seropositive end-stage renal disease
(ESRD) patients. (a). Moreover, the ratio
CD8+CD28+/CD28− (b) and CD57−/CD57+ (c)
were calculated to determine the differentiation
status of the CD8+ T cell compartment. ESRD
patients were dissected into a young (age < 50
years) and an old (age ≥ 50 years) group.
Individual dots are shown with the median for
the CMV-seronegative patient population (open
symbols) and the CMV-seropositive patients
(closed symbols). Significant differences
between groups are shown (one symbol:
P < 0·05; two symbols: P < 0·01; three symbols:
P < 0·001). Next, we determined the RTL within
a sorted CD28+ and CD28null CD8+ T cell
population from five elderly CMV-seropositive
ESRD patients (d). Individual data points are
shown and significant differences between the
two T cell fractions are shown (two symbols:
P < 0·01).
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induced an increase in the proliferation of CD4+ as well as
CD8+ T cells by determining the percentage of Ki-67+ T cells
(i.e. the percentage of T cells actually dividing). No signifi-
cant differences were observed in the percentage of Ki-67+
CD4+ or CD8+ T cells (CD4+Ki-67+ T cells; CMV-
seronegative: 2·09% ± 0·68 CMV-seropositive: 1·33% ± 0·52
and CD8+Ki-67+ T cells; CMV-seronegative: 1·99% ± 0·60
CMV-seropositive: 1·34% ± 0·25).
Discussion
The results of this study show that CMV-seropositivity is
associated with more differentiated memory CD4+ and
CD8+ T cell compartments. These highly differentiated T
cells show loss of CD28 expression, increased expression of
CD57 and shorter telomeres. CMV did not affect the thymic
output of new naive T cells, and therefore CMV-
seropositivity impacts only partly upon the ESRD-related
immunological ageing of the T cell system.
In a previous study [10], we observed that the character-
istics of the peripheral T cell system of ESRD patients are
very similar to healthy individuals with a chronological age
that is, on average, 20–30 years older. One of the salient
findings in ESRD patients and elderly healthy individuals
was a decreased number of circulating naive T cells [10].
In humans, the thymus is the single organ involved in
naive T cell generation. Ageing results in involution of the
thymus with subsequent decrease in TREC content within
the circulating T cell population. Because TREC content is
related reliably and linearly with age, measuring the TREC
content in blood can be used as a tool for age determination
for forensic purposes [12]. In both ESRD patients and
elderly healthy individuals a decreased thymic output of
naive T cells based upon TREC analysis was observed. Next
to the TREC content, an alternative technique to identify
recent thymic emigrants is to measure the CD31 expression
on naive T cells [19], which corroborates the findings of the
TREC content. In addition, activation and increased
numbers of proliferating Ki-67+ naive T cells were observed.
Homeostatic proliferation occurs in response to this
decreased thymic output to maintain the naive T cell com-
partment. Our findings do not support a role for CMV in
the decreased output of naive T cells or their peripheral
proliferation in the periphery, as both the TREC content
and the percentage of CD31+ and Ki-67+ cells were not
affected by CMV serostatus. This also suggests that the
expansion and differentiation of memory T cells in CMV-
seropositive patients does not change the number or
homeostatic proliferation of naive T cells. This may have
been expected, as it is assumed that increased turnover of
this compartment would also accelerate the turnover of
naive T cells.
Another parameter to assess the immunological age of T
cells is to determine the telomere length of CD4+ and CD8+
T cells, which is indicative of the proliferative history of the
cells. Similarly to TREC content, overall there is a clear
inverse correlation between RTL and age in both healthy
individuals and ESRD patients. However, the CD8+ T cells
of CMV-infected ESRD patients have substantially shorter
telomeres than age-matched CMV-seronegative ESRD
patients, resulting in an immunological age difference of
almost 20 years. This finding indicates a higher burden by
CMV on CD8+ T cells of ESRD patients during ageing. We
could not detect this CMV-related effect in RTL for the
CD4+ T cells. The absence of additional CMV-induced
telomere attrition within total CD4+ T cells in ESRD
patients in contrast to that within total CD8+ T cells can
therefore be explained by the difference in differentiation
status of the T cell compartment. To examine whether the
telomere shortage in CD8+ T cells is caused by a possible
inhibitory effect on the activity of the telomerase enzyme
(responsible for extending the telomere length), we analysed
the activity of this enzyme in both CD8+ and CD4+ T cell
populations. No differences were found between the CMV-
seronegative and CMV-seropositive patients, indicating that
altered telomerase activity is not a probable cause for the
decreased RTL in CD8 T cells of CMV-seropositive ESRD
patients. This indicates that the shorter telomeres for the
CD8+ T cell compartment is caused by the higher prolifera-
tion and differentiation status in CMV-seropositive
patients.
CMV infection induces a shift within both CD4+ and
CD8+ T cells towards the memory compartment. Specifi-
cally, the increase of CD28null T cells within the CD4+ and
CD8+ T cell compartment is highly associated with a previ-
ous CMV infection [14,20,21]. However, CD8+ memory T
cells contain far more CD28null as well as CD57+ T cells
when compared to CD4+ T cells. These differentiated T cells
are known to have short telomeres [16,22], which we could
confirm for ESRD patients in this study. The CD57-
expressing cells are found predominantly within the CD2-
negative memory T cells, implying that most of the
senescent cells are located within this memory fraction and
are found to be higher in CMV-seropositive ESRD patients.
As we did not detect an increase in the number of Ki-67+
T cells in the CMV-seropositive patients, we could not
establish a higher turnover of memory T cells. This might
suggest that, after initial expansion of this cell population
shortly after CMV infection [23], these cells will enter a
more exhausted state during chronic latency of the virus.
This results in a loss of capacity to proliferate accompanied
by an increased resistance to apoptosis [24].
Like ESRD patients, individuals infected with human
immunodeficiency virus (HIV) have T cell deficiencies
which resemble premature T cell ageing, caused probably by
continuous triggering of the immune system by the virus
[25]. Although the mechanism of creating a prematurely
aged T cell compartment for both diseases is different,
the end result on T cells is similar (i.e. higher number
of differentiated cells with a loss in CD28 expression,
R. W. J. Meijers et al.
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shorter telomeres and a lower number of naive T cells),
resulting in similar clinical outcomes such as a higher risk
for infections, development of cancer and cardiovascular
diseases [26].
In HIV-infected individuals, CMV causes an increase in
EMRA CD8+CD28null T cells expressing CD57. These highly
differentiated cells are positive for the effector cytotoxins
perforin and granzyme B [27,28]. In HIV patients it was
found that strong anti-CMV T cell responses result in a
lower number of naive T cells for the CD4 T cell compart-
ment [28]. These CMV effects found in HIV patients are in
line with CMV effects in ESRD patients.
We have postulated previously that the prematurely aged
T cell system in ESRD patients contributes to clinically rel-
evant complications, such as increased infection risk,
decreased vaccination response and a highly increased risk
for cardiovascular diseases [2,5,6,29–31]. Given their
cardiotoxic features, the proinflammatory and highly
cytotoxic CD4+CD28null T cells in ESRD patients can be
important for later complications [8]. A number of earlier
reports have also shown the relation between CMV
serostatus, the expansion of CD28null T cells and the
increased risk for atherosclerosis in ESRD patients [6–9]. In
addition, increased numbers of highly differentiated CD8+
T cell numbers and a loss of CD28 expression were associ-
ated with less allograft rejection after kidney transplanta-
tion. Given the results of this study, it seems unlikely that
primary immune responses which involve the naive T cell
compartment or CD4+ T cell-dependent immune responses
in ESRD patients will be affected by their CMV serostatus.
At present, such an association has not been reported and
CMV serostatus does not seem to affect the vaccination
response in children [32,33].
In healthy elderly individuals, CMV seropositivity leads
to an expansion of effector CD8+ T cells which are
CD8+CD28nullCD57+. These CMV-specific T cells were
found to be oligoclonal and can constitute to up to one-
quarter of the total CD8+ T cell compartment in elderly
which makes cells unable to respond to other pathogens
[34]. Moreover, these highly differentiated cells have shorter
telomeres and are associated with an increased risk for the
development of coronary heart diseases [35].
In conclusion, CMV-positive serostatus is associated with
an increased differentiation status of memory T cells and
telomere attrition of CD8+ T cells but does not explain
the premature T cell ageing associated with the uraemic
environment.
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Supporting information
Additional Supporting information may be found in the
online version of this article at the publisher’s website:
Fig. S1. Gating strategy of the CD4+ and CD8+ T cell
subsets. From whole blood we first selected for lymphocytes
(a); we then selected the CD3+ lymphocytes (T cells) (b)
and made a distinction between the CD4+ and CD8+ T cells
(c). On the basis of CCR7 and CD45RO, we divided the dif-
ferent subsets [naive, effector memory (EM), central
memory (CM) and end-stage renal disease (EMRA)] for the
CD4+ (d) and CD8 (e) T cell compartments.
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